MA40609B1 - Agents de liaison cd123 et leurs utilisations - Google Patents

Agents de liaison cd123 et leurs utilisations

Info

Publication number
MA40609B1
MA40609B1 MA40609A MA40609A MA40609B1 MA 40609 B1 MA40609 B1 MA 40609B1 MA 40609 A MA40609 A MA 40609A MA 40609 A MA40609 A MA 40609A MA 40609 B1 MA40609 B1 MA 40609B1
Authority
MA
Morocco
Prior art keywords
binding fragments
antibodies
binding agents
relates
antigen binding
Prior art date
Application number
MA40609A
Other languages
English (en)
Inventor
John Wheeler
Alexey Teplyakov
Francois Gaudet
Ricardo Attar
Benjamin C Harman
Yingzhe Li
Jinquan Luo
Ronan Mcdaid
Steven C Pomerantz
Susan H Tam
Sheng-Jiun Wu
Jennifer F Nemeth
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40609B1 publication Critical patent/MA40609B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des anticorps qui se lient de manière immunospécifique à cd123. L'invention concerne également des polynucléotides associés susceptibles de coder pour les anticorps fournis spécifiques au cd123 ou des fragments de liaison à l'antigène, des cellules exprimant les anticorps fournis ou les fragments de liaison, ainsi que des vecteurs associés et des anticorps marqués de manière détectable ou des fragments de liaison à l'antigène marqués de manière détectable. En outre, l'invent
MA40609A 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations MA40609B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05
PCT/US2015/048316 WO2016036937A1 (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA40609B1 true MA40609B1 (fr) 2020-05-29

Family

ID=54150667

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053145A MA53145A (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations
MA40609A MA40609B1 (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053145A MA53145A (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations

Country Status (39)

Country Link
US (1) US9850310B2 (fr)
EP (2) EP3722315A1 (fr)
JP (2) JP6805130B2 (fr)
KR (1) KR102540192B1 (fr)
CN (1) CN107074956B (fr)
AR (1) AR101765A1 (fr)
AU (1) AU2015311931B2 (fr)
CA (1) CA2959171C (fr)
CL (1) CL2017000515A1 (fr)
CO (1) CO2017002196A2 (fr)
CR (1) CR20170079A (fr)
CY (1) CY1122858T1 (fr)
DK (1) DK3189081T3 (fr)
EA (1) EA037647B1 (fr)
EC (1) ECSP17020812A (fr)
ES (1) ES2791249T3 (fr)
HR (1) HRP20200745T1 (fr)
HU (1) HUE048791T2 (fr)
IL (1) IL250770B (fr)
JO (1) JO3568B1 (fr)
LT (1) LT3189081T (fr)
MA (2) MA53145A (fr)
ME (1) ME03724B (fr)
MX (1) MX384424B (fr)
MY (1) MY186337A (fr)
NI (1) NI201700025A (fr)
PE (1) PE20171556A1 (fr)
PH (1) PH12017500472A1 (fr)
PL (1) PL3189081T3 (fr)
PT (1) PT3189081T (fr)
RS (1) RS60305B1 (fr)
SG (1) SG11201701599UA (fr)
SI (1) SI3189081T1 (fr)
SM (1) SMT202000253T1 (fr)
TW (1) TWI693233B (fr)
UA (1) UA120060C2 (fr)
UY (1) UY36289A (fr)
WO (1) WO2016036937A1 (fr)
ZA (1) ZA201702369B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
EP3812398A3 (fr) 2015-01-23 2021-07-21 Sanofi Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2017267793B2 (en) * 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017211731A1 (fr) 2016-06-06 2017-12-14 F. Hoffmann-La Roche Ag Protéines hybrides utilisées en ophtalmologie et assurant une meilleure rétention oculaire
KR20190015520A (ko) 2016-06-07 2019-02-13 마크로제닉스, 인크. 조합 치료법
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
AU2017331256B2 (en) 2016-09-21 2024-11-07 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
CA3049689A1 (fr) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions et methodes pour augmenter la signalisation de recepteurs mediee par des anticorps
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
WO2018160754A2 (fr) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Protéine monovalente inductible de fixation d' antigène
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CA3063362A1 (fr) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Proteines trispecifiques ciblant la msln et procedes d'utilisation
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
WO2019050521A1 (fr) * 2017-09-07 2019-03-14 Macrogenics, Inc. Schémas posologiques de diacorps bispécifiques cd123 x cd3 dans le traitement de malignités hématologiques
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
MX2020004381A (es) * 2017-10-27 2020-08-20 Pfizer Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
CR20200564A (es) 2018-05-24 2021-06-21 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (fr) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Protéines de liaison à dll3 et méthodes d'utilisation
US20220275081A1 (en) * 2018-10-17 2022-09-01 Good T Cells, Inc. Binding molecule specific for lrig-1 protein and use thereof
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN113874400B (zh) * 2019-03-11 2025-02-07 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
AU2020267504A1 (en) * 2019-05-08 2021-12-02 Janssen Biotech, Inc. Materials and methods for modulating T cell mediated immunity
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CN113912694B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白和应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
CA3170833A1 (fr) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Proteines de liaison a flt3 et methodes d'utilisation
KR20230051617A (ko) 2020-03-13 2023-04-18 얀센 바이오테크 인코포레이티드 Siglec-3/cd33을 결합시키기 위한 물질 및 방법
CN115666727A (zh) * 2020-05-19 2023-01-31 詹森生物科技公司 包含t细胞重定向治疗剂和vla-4粘附途径抑制剂的组合物
EP4153314A4 (fr) 2020-05-19 2024-05-22 The Regents of The University of California Polypeptides et vaccins conjugués d'induction de réponses immunitaires
AU2021339754A1 (en) 2020-09-11 2023-05-25 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
US12024559B2 (en) * 2020-10-23 2024-07-02 Asher Biotherapeutics, Inc. Fusions with CD8 antigen binding molecules for modulating immune cell function
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
RS66868B1 (sr) 2021-01-28 2025-06-30 Regeneron Pharma Kompozicije i postupci za lečenje sindroma oslobađanja citokina
CA3220458A1 (fr) * 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprenant un agent therapeutique de redirection des lymphocytes t et un agent therapeutique anti-cd44
GB2638094B (en) 2021-05-19 2026-03-04 Asher Biotherapeutics Inc IL-21 Polypeptides And Targeted Constructs
WO2023019121A2 (fr) * 2021-08-09 2023-02-16 Merck Patent Gmbh Protéines désaccouplant la cytotoxicité tumorale à médiation par les lymphocytes t de la libération de cytokines pro-inflammatoires
WO2023138666A1 (fr) * 2022-01-19 2023-07-27 Utc Therapeutics (Shanghai) Co., Ltd. Arn circulaire et son utilisation
CA3247475A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物
JP2026506095A (ja) 2023-02-17 2026-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1538206B1 (fr) 1997-09-16 2010-03-24 Centocor, Inc. Synthèse chimique complète et synthèse de gènes et de génomes
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2577082A1 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
JP5694923B2 (ja) * 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011038301A2 (fr) * 2009-09-25 2011-03-31 Xoma Technology Ltd. Procédés de criblage
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
ES2924722T3 (es) * 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3

Also Published As

Publication number Publication date
ME03724B (fr) 2021-01-20
PT3189081T (pt) 2020-05-25
PE20171556A1 (es) 2017-10-27
JO3568B1 (ar) 2020-07-05
MY186337A (en) 2021-07-13
UY36289A (es) 2016-04-01
WO2016036937A1 (fr) 2016-03-10
JP2017529838A (ja) 2017-10-12
CY1122858T1 (el) 2021-05-05
EP3722315A1 (fr) 2020-10-14
CA2959171A1 (fr) 2016-03-10
SI3189081T1 (sl) 2020-07-31
PH12017500472A1 (en) 2017-07-31
PL3189081T3 (pl) 2020-10-05
EP3189081B1 (fr) 2020-02-19
BR112017004322A2 (pt) 2017-12-05
HRP20200745T1 (hr) 2020-08-07
EA037647B1 (ru) 2021-04-27
MA53145A (fr) 2021-05-19
ECSP17020812A (es) 2018-07-31
TWI693233B (zh) 2020-05-11
KR20170049554A (ko) 2017-05-10
TW201625687A (zh) 2016-07-16
CN107074956A (zh) 2017-08-18
AR101765A1 (es) 2017-01-11
ES2791249T3 (es) 2020-11-03
DK3189081T3 (da) 2020-05-04
CL2017000515A1 (es) 2018-03-16
MX384424B (es) 2025-03-14
LT3189081T (lt) 2020-05-11
NI201700025A (es) 2017-06-22
AU2015311931A1 (en) 2017-03-16
AU2015311931B2 (en) 2020-09-03
HUE048791T2 (hu) 2020-09-28
IL250770A0 (en) 2017-04-30
US9850310B2 (en) 2017-12-26
UA120060C2 (uk) 2019-09-25
SG11201701599UA (en) 2017-03-30
MX2017002891A (es) 2017-10-11
EP3189081A1 (fr) 2017-07-12
US20160068605A1 (en) 2016-03-10
RS60305B1 (sr) 2020-07-31
CN107074956B (zh) 2021-11-26
IL250770B (en) 2020-10-29
EA201790530A1 (ru) 2018-03-30
KR102540192B1 (ko) 2023-06-02
JP2021050216A (ja) 2021-04-01
CR20170079A (es) 2017-04-27
JP6805130B2 (ja) 2020-12-23
CA2959171C (fr) 2023-11-14
ZA201702369B (en) 2018-12-19
SMT202000253T1 (it) 2020-07-08
CO2017002196A2 (es) 2017-07-28

Similar Documents

Publication Publication Date Title
SA520420631B1 (ar) الأجسام المضادة لـ cd3 واستخداماتها
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
MA38498A1 (fr) Protéines de liaison anti-lag-3
NZ700650A (en) Anti-hla-b*27 antibodies and uses thereof
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
JO3798B1 (ar) الأجسام المضادة ملزمة على وجه التحديد pd-1 واستخداماتها
MX383216B (es) Anticuerpos dirigidos contra la inmunoglobulina de células t y la proteína mucina 3 (tim-3).
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
MD20140108A2 (ro) Anticorpi împotriva metaloproteinazei 9 matriciale
PH12016500943A1 (en) Aplnr modulatros and uses thereof
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MY161435A (en) Anti-vegf antibodies and polynucleotides encoding the same
EA201591716A1 (ru) Антитела анти-il-33 и их применение
SG10201805934RA (en) Antibodies directed against interleukin-33 (il-33)
SG196839A1 (en) Antibodies against fcrn and use thereof
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
MX382398B (es) Proteinas de union a antigeno st2.
MD20140107A2 (ro) Anticorpi împotriva metaloproteinazei 9 din matrice
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
PH12018501902A1 (en) Gitr antibodies, methods, and uses
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.